Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy
Open Access
- 29 July 2009
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (15), 4806-4814
- https://doi.org/10.1158/1078-0432.ccr-09-0344
Abstract
A long-term goal of pharmacogenomics research is the design of individualized therapy based on the genomic sequence of the patient, in order to maximize response and minimize adverse drug reactions. Pharmacoethnicity, or ethnic diversity in drug response or toxicity, is becoming increasingly recognized as an important factor accounting for interindividual variation in anticancer drug responsiveness. Although pharmacoethnicity is determined by genetic and nongenetic factors, there is rapidly accumulating clinical evidence about ethnic differences in the frequencies of polymorphisms within many of the important cancer drug-related genes. This article reviews the current clinical evidence for ethnic differences in anticancer drug disposition and sensitivity while highlighting the challenges, and potential solutions, to acquiring such knowledge. The discovery of “ethnic-specific genetic signatures,” representing unique sets of drug susceptibility-governing polymorphisms, may be the outcome of such work. Ultimately, such understanding will further the lofty goal of individualization of chemotherapy based on a person's unique genetic make-up to improve the tolerability and effectiveness of chemotherapy for all patients.Keywords
This publication has 67 references indexed in Scilit:
- Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicityBlood, 2009
- Genome-wide association studies: implications for multiethnic samplesHuman Molecular Genetics, 2008
- Identification of Genetic Variants Contributing to Cisplatin-Induced Cytotoxicity by Use of a Genomewide ApproachAmerican Journal of Human Genetics, 2007
- A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicityProceedings of the National Academy of Sciences of the United States of America, 2007
- Mapping Genes that Contribute to Daunorubicin-Induced CytotoxicityCancer Research, 2007
- Ancestry and pharmacogenetics of antileukemic drug toxicityBlood, 2007
- Effect of population and gender on chemotherapeutic agent–induced cytotoxicityMolecular Cancer Therapeutics, 2007
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2005